Dividend proposal increase of 17%

February 10, 2011 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, announces that the Board plans to propose a dividend of €0.07 per share for the year ended 31 December 2010 (2009: €0.06) , a 17% increase on last year.

read more

Acquisition of Serbian distributor

February 3, 2011 Group News
Tags
,

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has acquired a 70% interest in its Serbian distributor, Life R.F. doo (‘Life R.F.’).

Cryo-Save paid an initial consideration of €2.3 million payable in cash and 30,000 Cryo-Save Group N.V. shares, with an option to acquire the remaining 30% of the shares of Life R.F. in the next 3 years.

The Group expects the acquisition to be earnings enhancing with immediate effect.

read more

Share buyback tranche successfully completed

January 14, 2011 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, announced that it has completed the tranche of its share buyback programme as announced on 6 January 2011.

The Group has repurchased 100,000 shares during the period 6 January 2011 until 12 January 2011. The shares were repurchased at an average price of € 5.20.

read more

Director/PDMR shareholding

January 10, 2011 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has been informed that Mr Ronald Lorijn, Non-Executive Director, purchased 7,354 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €4.99 on 7 January 2011.

Following this purchase, Ronald Lorijn is beneficially interested in 7,354 ordinary shares, representing approximately 0.08% of the Group’s issued share capital.

read more

Buyback of shares

January 6, 2011 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, announces that it has commenced a new tranche of its share buyback programme.

Based on the authorization granted by the General Meeting of Shareholders on 19 May 2010, Cryo-Save intends to buy 100,000 shares representing approximately 1% of its outstanding shares. This tranche of the share buyback programme will have a maximum value of approximately EUR 0.5 million based on the stock price at 4 January 2011, and will be funded by the Group’s existing cash reserves.

read more

Announcement of a “block trade” for the share buyback programme

January 6, 2011 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, announces that it has reached an agreement with a shareholder regarding the buyback of 80,000 shares via its bank Kempen & Co. The price for the shares is set at EUR 5.20 per share.

This block trade is part of the share buyback programme as announced in this morning’s press release.

read more

Cryo-Save to launch Cryo-Lip™ in the US

December 16, 2010 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, “Cryo-Save”), Europe’s leading stem cell bank, today announced that it intends to launch Cryo-Lip™ in the United States in 2011, after the successful introduction of the service in Europe during 2010. Cryo-Save is one of the first in the world that offers cryostorage of adult mesenchymal stem cells from fatty tissue for use by patients undergoing a surgical procedure. Cryo-Save is currently looking for partners to roll out this service in the United States.

read more

Director/PDMR shareholding

December 15, 2010 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has been informed that Mr Walter van Pottelberge, Non-Executive Director, purchased 5,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €4.90 on 13 December 2010.

Following this purchase, Walter van Pottelberge is beneficially interested in 31,210 ordinary shares, representing approximately 0.33% of the Group’s issued share capital.

read more